Le Lézard
Classified in: Health, Business
Subjects: TAXES, HEALTH

JDRF advocates for all Canadians living with type 1 diabetes to be eligible for the Disability Tax Credit


JDRF advocates for all Canadians living with type 1 diabetes to be eligible for the Disability Tax Credit

TORONTO, Oct. 23, 2017 (GLOBE NEWSWIRE) -- JDRF Canada believes that every Canadian with type 1 diabetes should qualify for the Disability Tax Credit. The costs of managing type 1 diabetes are growing, creating more inequity between those who must pay additional disability expenses and other taxpayers. The purpose of the Disability Tax Credit is to provide greater tax equity by allowing some relief for disability costs.

JDRF believes the Canada Revenue Agency (CRA) interpretation of the rules regarding life-sustaining therapy have now changed, resulting in many Canadians with type 1 diabetes being denied the tax relief they're eligible for under the Disability Tax Credit.

The out-of-pocket costs of managing type 1 diabetes are significant ? and can cost up to $15,000 annually, depending on individual and provincial insurance coverage. To qualify for the Disability Tax Credit, medical practitioners must certify that people spend more than 14 hours per week administering insulin therapy and blood glucose testing. JDRF remains concerned that the advice of medical practitioners is no longer being accepted by the CRA.

On October 20, JDRF addressed members of Canada's Standing Committee on Finance, advocating to make this benefit more widely available to all Canadians living with type 1 diabetes. The CRA has invited JDRF to meet on October 25 to discuss this issue further.

?Our constituents have voiced their frustration with the CRA's recent interpretation of the eligibility criteria for the Disability Tax Credit. This is complex and time-consuming disease and we are speaking up on behalf of all Canadians living with type 1 diabetes. We will continue advocating to ensure their concerns are heard,? says Dave Prowten, President and CEO, JDRF Canada.

For more information on the Disability Tax Credit qualifications, please click here

For more information on JDRF click here.

About JDRF Canada

JDRF is the leading global organization funding type 1 diabetes research. Our goal is to raise funds to support the most advanced international type 1 diabetes research and progressively remove the impact of this disease from people's lives ? until we achieve a world without type 1 diabetes. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure type 1 diabetes. JDRF is the largest charitable supporter of type 1 diabetes research. For more information, please visit jdrf.ca.

Media Contact

Chloé Roussel
National Bilingual Communications Specialist
JDRF Canada
[email protected] 
647.789.2459


These press releases may also interest you

at 16:20
Cartesian Therapeutics, Inc. (the "Company"), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On May 1, 2024,...

at 16:15
Profound Medical Corp. ("Profound" or the "Company"), a...

at 16:10
Veracyte, Inc. , a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers...

at 16:10
Kezar Life Sciences, Inc. , a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of...

at 16:10
Injectsense Inc., a sensor-enabled digital health company,?announced that the ethics committee at the Centro de la Vision Clinic in Santiago, Chile, has approved a 20-patient study that will confirm safety and effectiveness of the company's...

at 16:09
Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced that its abstract, In Vivo Generation of ?CD19-CAR T Cells Using a Novel LV-based Platform Successfully Clears Advanced...



News published on and distributed by: